Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
14.25
-0.02 (-0.16%)
NASDAQ · Last Trade: Nov 5th, 1:44 PM EST
Detailed Quote
Previous Close
14.27
Open
13.78
Bid
14.24
Ask
14.26
Day's Range
13.33 - 14.44
52 Week Range
6.550 - 16.20
Volume
1,810,852
Market Cap
1.83B
PE Ratio (TTM)
25.44
EPS (TTM)
0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,521,105
Chart
About Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Aurinia Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies to treat autoimmune and rare diseases. The company is dedicated to advancing its pipelines, particularly in developing treatments for conditions such as lupus nephritis, with a commitment to improving patient outcomes through scientifically driven solutions. Aurinia’s goal is to bring forward novel medications that address unmet medical needs and transform the standard of care in its therapeutic areas. Read More
Things got murkier at the FDA’s drug evaluation agency as its acting director stepped down, alleging that a new drug approval program injected politics, superseding decisions based on science.
Discover Aurinia Pharmaceuticals (AUPH), a top growth stock with explosive earnings, soaring revenue, and high ROE, using Louis Navellier's proven investment strategy.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS® (voclosporin) at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24–29, and the American Society of Nephrology (ASN) Kidney Week 2025, taking place in Houston, TX, November 5–9.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025.
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.
Aurinia Pharmaceuticals (AUPH) is a top growth stock pick based on Louis Navellier's strategy, showing explosive earnings growth, strong sales momentum, and rising profit margins.
Aurinia Pharma (AUPH) shows strong growth momentum with surging earnings, impressive sales growth, and major margin expansion, making it a top pick for growth investors.
Aurinia Pharmaceuticals (AUPH) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, sales growth, and improving margins. The stock shows solid financial health and reasonable valuation.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release second quarter 2025 financial and operational results before markets open on July 31, 2025.
Aurinia Pharmaceuticals (NASDAQ:AUPH) shows strong growth metrics, including surging earnings, revenue, and cash flow, making it a candidate for investors following Louis Navellier’s strategy.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). The study investigated aritinercept doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg and 300 mg and placebo, administered by subcutaneous injection, in 61 healthy subjects.
